Tumor-induced CD14+HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients

Cancer Immunology, Immunotherapy

Volumn 64, Issue 3, 2015, Pages 389-399

  Wang, Zhitao ^a   Zhang, Lulu ^a   Wang, Huiping ^a   Xiong, Shudao ^a   Li, Yanli ^a   Tao, Qianshan ^a   Xiao, Weihua ^b   Qin, Hui ^a   Wang, Yiping ^c   Zhai, Zhimin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bortezomib; Immunosuppression; Multiple myeloma; Myeloid derived suppressor cells; Tumor progressive

Indexed keywords

ARGINASE 1; BORTEZOMIB; CD14 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; VINCRISTINE; BORONIC ACID DERIVATIVE; CYTOKINE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CARCINOGENESIS; CELL FUNCTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOID DERIVED SUPPRESSOR CELL; MYELOID PROGENITOR CELL; PLASMA; PRIORITY JOURNAL; SUPPRESSOR CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; BLOOD; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL GROWTH; DISEASE COURSE; IMMUNOLOGY; PATHOLOGY; REGULATORY T LYMPHOCYTE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; BORONIC ACIDS; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL GROWTH PROCESSES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOID CELLS; PYRAZINES; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84925534592     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1646-4     Document Type: Article

References (43)

1. Galustian C, Meyer B, Labarthe MC et al (2009) The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033–1045. doi:10.1007/s00262-008-0620-4
2. Scheid C, Sonneveld P, Schmidt-Wolf IG et al (2014) Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 99:148–154. doi:10.3324/haematol.2013.087585
3. Niesvizky R (2013) Immunomodulatory agents changing the landscape of multiple myeloma treatment. Crit Rev Oncol Hematol 88(Suppl 1):S1–S4. doi:10.1016/j.critrevonc.2012.12.011
4. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563–579. doi:10.1111/j.1365-2141.2007.06705.x
5. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI (2010) Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 184:3106–3116. doi:10.4049/jimmunol.0902661
6. Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563. doi:10.1158/0008-5472.CAN-07-6229
7. Srivastava MK, Zhu L, Harris-White M et al (2012) Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 7:e40677. doi:10.1371/journal.pone.0040677
8. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506
9. Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C (2012) Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol Immunother 61:1319–1325. doi:10.1007/s00262-012-1269-6
10. Kusmartsev S, Gabrilovich DI (2002) Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 51:293–298. doi:10.1007/s00262-002-0280-8
11. Manjili MH (2012) Phenotypic plasticity of MDSC in cancers. Immunol Investig 41:711–721. doi:10.3109/08820139.2012.673670
12. Greten TF, Manns MP, Korangy F (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11:802–807. doi:10.1016/j.intimp.2011.01.003
13. Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F (2012) S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 136:176–183. doi:10.1111/j.1365-2567.2012.03566.x
14. Liu CY, Wang YM, Wang CL et al (2010) Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(−)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 136:35–45. doi:10.1007/s00432-009-0634-0
15. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69:1553–1560. doi:10.1158/0008-5472.CAN-08-1921
16. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135:234–243. doi:10.1053/j.gastro.2008.03.020
17. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd (2013) Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 140:13–21. doi:10.1007/s10549-013-2618-7
18. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420. doi:10.1200/JCO.2005.04.242
19. Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473. doi:10.1038/sj.leu.2404284
20. Rudolph BM, Loquai C, Gerwe A, Bacher N, Steinbrink K, Grabbe S, Tuettenberg A (2014) Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp Dermatol 23:202–204. doi:10.1111/exd.12336
21. Huang A, Zhang B, Wang B, Zhang F, Fan KX, Guo YJ (2013) Increased CD14(+)HLA-DR (−/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 62:1439–1451. doi:10.1007/s00262-013-1450-6
22. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB (2011) Immunosuppressive CD14+ HLA-DR(low)/− monocytes in B-cell non-Hodgkin lymphoma. Blood 117:872–881. doi:10.1182/blood-2010-05-283820
23. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, Romano E, Speiser DE (2014) Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63:247–257. doi:10.1007/s00262-013-1508-5
24. Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, Nakamoto Y, Kaneko S (2013) Increase in CD14+ HLA-DR −/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 62:1421–1430. doi:10.1007/s00262-013-1447-1
25. Payne KK, Zoon CK, Wan W, Marlar K, Keim RC, Kenari MN, Kazim AL, Bear HD, Manjili MH (2013) Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Res Treat 142:45–57. doi:10.1007/s10549-013-2733-5
26. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59. doi:10.1007/s00262-008-0523-4
27. Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13:739–752. doi:10.1038/nrc3581
28. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593–1600. doi:10.1007/s00262-010-0855-8
29. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68–77. doi:10.1158/0008-5472.CAN-09-2587
30. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H (2005) Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 93:273–278. doi:10.1038/sj.bjc.6602702
31. Yan-Li L, Kang-Sheng G, Yue-Yin P, Yang J, Zhi-Min Z (2014) The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leuk Res 38:323–328. doi:10.1016/j.leukres.2013.12.005
32. Gorgun GT, Whitehill G, Anderson JL et al (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121:2975–2987. doi:10.1182/blood-2012-08-448548
33. Favaloro J, Liyadipitiya T, Brown R et al (2014) Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma. doi:10.3109/10428194.2014.904511
34. Yuan XK, Zhao XK, Xia YC, Zhu X, Xiao P (2011) Increased circulating immunosuppressive CD14(+)HLA-DR(−/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res 39:1381–1391
35. Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185:2273–2284. doi:10.4049/jimmunol.1000901
36. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF (2012) Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 90:1343–1355. doi:10.1007/s00109-012-0916-x
37. Schafer ZT, Brugge JS (2007) IL-6 involvement in epithelial cancers. J Clin Investig 117:3660–3663. doi:10.1172/JCI34237
38. Letterio JJ, Roberts AB (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137–161. doi:10.1146/annurev.immunol.16.1.137
39. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, Masuyama K (2012) Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci 103:976–983. doi:10.1111/j.1349-7006.2012.02248.x
40. Li H, Han Y, Guo Q, Zhang M, Cao X (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182:240–249
41. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC (2002) Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem 277:21123–21129. doi:10.1074/jbc.M110675200
42. Raber P, Ochoa AC, Rodriguez PC (2012) Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Investig 41:614–634. doi:10.3109/08820139.2012.680634
43. McBride A, Ryan PY (2013) Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 13:339–358. doi:10.1586/era.13.9